Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 202: Sotorasib vs Pembrolizumab in 1L KRAS G12C-Mutated, PD-L1 Negative Advanced NSCLC
NCT05920356Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Nov 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 38
01
Overview
A Phase 3 trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Nov 2023; status: recruiting.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05920356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920356.